AdvanTIG-301 is an ongoing phase 3, randomized, open-label study to compare tislelizumab plus ociperlimab plus concurrent chemoradiotherapy (cCRT) followed by tislelizumab plus ociperlimab versus cCRT followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer (NSCLC).
Poster from ELCC 2022 describing AdvanTIG-204, a phase 2 randomized multicenter, open-label study of patients with treatment naïve (TN) limited-stage small cell lung cancer (LS-SCLC) investigating the synergistic effects of ociperlimab, tislelizumab and chemoradiotherapy (cCRT).
Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1
monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene solid tumor pipeline and clinical trials.
Dr Benjamin Besse discusses targeting other components of immune checkpoint including TIGIT, TIM-3 and OX40 in immunotherapy combinations.
